(Q40307963)
Statements
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer (English)
Seiji Nagashima
Mikio Oka
Takeshi Kitazaki
Ken Shiozawa
Yoichi Nakamura
Masaaki Takemura
Hikaru Yabuuchi
Minoru Fukuda
Kazuhiro Tsukamoto